Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (168)

« Back to Publications

Inhibition of MLLT1 limits growth of KMT2A::AFF1 leukaemias without killing healthy haematopoietic stem cells

Rajhansa S. et al, (2026), Experimental Hematology, 105458 - 105458

Discovery and Characterization of a Nonacidic Small-Molecule Inhibitor of the Sodium-Coupled Dicarboxylate Transporter NaCT.

Quigley A. et al, (2026), Journal of medicinal chemistry

Inhibition of MLLT1 limits growth of MLL-AF4 leukaemias without killing healthy haematopoietic stem cells

Rajhansa S. et al, (2025)

Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse.

Edmonds AK. et al, (2025), Journal of medicinal chemistry, 68, 9638 - 9660

Binding-Site Purification of Actives (B-SPA) Enables Efficient Large-Scale Progression of Fragment Hits by Combining Multi-Step Array Synthesis With HT Crystallography.

Grosjean H. et al, (2025), Angewandte Chemie (International ed. in English), 64

Covalent Inhibitors of S100A4 Block the Formation of a Pro-Metastasis Non-Muscle Myosin 2A Complex

Giroud C. et al, (2024), Journal of Medicinal Chemistry, 67, 18943 - 18956

Engineered HMGB1 construct with tandem Box B domains promotes tissue regeneration without potential for inflammation

Guitart ÁV. et al, (2024)

Enabling equitable and affordable access to novel therapeutics for pandemic preparedness and response via creative intellectual property agreements

Griffen EJ. and Boulet P., (2024), Wellcome Open Research, 9, 374 - 374

Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist

Balıkçı E. et al, (2024), Journal of Medicinal Chemistry, 67, 7245 - 7259

Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases.

Henderson SH. et al, (2024), European journal of medicinal chemistry, 269

Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor.

Xiong Y. et al, (2024), Journal of medicinal chemistry, 67, 5837 - 5853

Discovery of PFI-6, a small-molecule chemical probe for the YEATS domain of MLLT1 and MLLT3

Raux B. et al, (2024), Bioorganic & Medicinal Chemistry Letters, 98, 129546 - 129546

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors

Boby ML. et al, (2023), Science, 382

Turning high-throughput structural biology into predictive inhibitor design

Saar KL. et al, (2023), Proceedings of the National Academy of Sciences, 120

Discovery and Development Strategies for SARS-CoV-2 NSP3 Macrodomain Inhibitors

Schuller M. et al, (2023), Pathogens, 12, 324 - 324

Load More

1
2
3
4
5
6
7
...
»